Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant Effect on Cough Reflex Sensitivity
NCT02476890Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of gefapixant in refractory chronic cough (RCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Cough Reflex Sensitivity to Capsaicin, Cough Reflex Sensitivity to Citric Acid and 2 more. Started Oct 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT02476890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476890.